
Sign up to save your podcasts
Or


Q1 is in the books, and stocks are heading into Q2 with some major accomplishments. Can the market rally keep raging? And where you should be positioned going into the second quarter. Plus… what it really costs to craft these diabetes drugs. A new study pointing to a $5 price tag for a month’s worth of one blockbuster GLP-1 drug. The dollar dichotemy… and if prices will come down for the public.
Fast Money Disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By CNBC3.9
12441,244 ratings
Q1 is in the books, and stocks are heading into Q2 with some major accomplishments. Can the market rally keep raging? And where you should be positioned going into the second quarter. Plus… what it really costs to craft these diabetes drugs. A new study pointing to a $5 price tag for a month’s worth of one blockbuster GLP-1 drug. The dollar dichotemy… and if prices will come down for the public.
Fast Money Disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

4,089 Listeners

3,222 Listeners

239 Listeners

149 Listeners

326 Listeners

67 Listeners

154 Listeners

2,161 Listeners

2,112 Listeners

595 Listeners

551 Listeners

20 Listeners

1,555 Listeners

208 Listeners

412 Listeners

305 Listeners

123 Listeners

807 Listeners

179 Listeners

61 Listeners

160 Listeners

36 Listeners

12 Listeners

22 Listeners

13 Listeners

16 Listeners